Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells

Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). In NSCLC patients, an EGFR mutation is likely to be correlated with high levels of expressi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta pharmacologica Sinica 2017-11, Vol.38 (11), p.1512-1520
Hauptverfasser:	Jiang, Xiao-Ming, Xu, Yu-Lian, Huang, Mu-Yang, Zhang, Le-Le, Su, Min-Xia, Chen, Xiuping, Lu, Jin-Jian
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides Actinomycin Aniline Compounds Antineoplastic Agents - pharmacology Apoptosis B7-H1 Antigen - genetics B7-H1 Antigen - metabolism Biodegradation Biomedical and Life Sciences Biomedicine Bortezomib Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Chloroquine Cycloheximide Dose-Response Relationship, Drug Down-Regulation Enzyme inhibitors Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Gene expression Gene Expression Regulation, Neoplastic Glycogen Synthase Kinase 3 beta - metabolism Glycosylation Humans Immunology Internal Medicine Kinases L1 protein Ligands Lithium chloride Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - pathology Lymphocytes Lymphocytes T Medical Microbiology Mutation Non-small cell lung carcinoma Original original-article PD-L1 protein Phagocytosis Pharmacology/Toxicology Phosphorylation Piperazines - pharmacology Post-translation Proteasome Endopeptidase Complex Proteasome inhibitors Protein Kinase Inhibitors - pharmacology Protein-tyrosine kinase Proteolysis RNA, Messenger - genetics RNA, Messenger - metabolism Targeted cancer therapy Time Factors Transcription Tumor Microenvironment Tunicamycin Vaccine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!